TSC-101 Updated Nov 13
TSC-101's development is paused, and the stock's fate hinges entirely on whether TScan can secure a partnership for the heme program. Without a partner, the Phase 3 trial will not resume and the program may be abandoned. The company's focus has shifted to preclinical solid tumor candidates, which are years from clinical data. Monitor for partnership announcements or a potential sale of the heme assets.
- Phase 1 data were strong: 11 of 14 patients achieved complete donor chimerism within ~3 weeks of first infusion, and all 5 patients assessed after a second infusion also achieved complete chimerism.
- The FDA agreed on the pivotal study design for TSC-101, reducing regulatory risk if a partner picks up the program.
- The company has $73M in cash extending into Q4 2027, providing time to find a partner for the heme program.
- The Phase 3 ALLOHA-2 trial is paused due to insufficient capital, with no guarantee a partner will be found to fund completion.
- TScan cut 75% of its workforce and the CEO stated the company is 'pausing further development in the heme program', effectively deprioritizing TSC-101.
- Three analysts downgraded the stock in early September 2026 (Needham to Hold, Wedbush to Neutral, HC Wainwright to Neutral).